The Saddest Restaurant Closings in Charleston, August 2025
August is historically slow for the food and beverage industry in Charleston, and several establishments have announced their closures. Restaurants include a Lowcountry icon, a West Ashley bistro, and a Daniel Island staple.
Charleston Grill shuts down after 36 years
It's last call for crabcakes on Saturday, August 23, as fine dining hotel restaurant Charleston Grill shuts its doors to make way for a new restaurant. The Post and Courier broke the news yesterday that the restaurant will shutter after 36 years in service. Closing Charleston Grill is part of the overhaul of the Charleston Place after the Beemok Hospitality Collection (BHC) acquired it in 2021. 'A fresh new dining concept is planned for the future,' says BHC president Casey Lavin, 'And in the meantime, guests can expect a unique pop-up culinary concept to debut in the coming months.'
Charleston Grill has been through several changes since opening in 1989 with chef Louis Osteen at the helm. Chef Bob Waggoner took over in 1997 with sous chef Michelle Weaver, who would later lead the kitchen in 2009. Longtime general manager Mickey Bakst set the tone for the front of the house for 17 years, before retiring in 2020. Throughout the changes however, remained a upstanding fine dining establishment exhalting Lowcountry fare in a refined manner. It will be interesting to see what's next for the space.
Bonjuor to La Bonne Franquette
West Ashley bistro La Bonne Franquette recently announced that Sunday, August 31, will be its last day. In an Instagram post, owner Carly Paume writes, 'The decision has not been easy for me and I've tried to consider all alternatives but life takes unexpected turns. Your support and loyalty from the moment we started throwing paint on the building has meant the world to me. We have loved spending special moments with you and will miss our times with you. Many of you have become a family for us and we hope to see you in our future chapters.'
La Bonne Franquette was known for its fine French fare, especially brunch, and its adorable patio with colorful umbrellas.
Turnover on Daniel Island
Chef-artist Sermet Aslan will close his eponymous restaurant, Sermet's Courtyard, on Wednesday, August 20. Aslan has moved his cafe over the years, from West Ashley to King Street to James Island and lastly to Daniel Island. According to The Post and Courier, the team from Nick's German Kitchen, Nick and Kelly Ruhotina, will take over the 115 River Landing Drive space to open Vinea Courtyard Kitchen, a restaurant 'rooted in European flavors.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones. 'With our recently announced funding agreement in place, we are well positioned to continue advancing our lead clinical programs, CYB003 and CYB004, through multiple inflection points,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Gaining European CTA approval and MHRA approval to commence EMBRACE in the UK has enabled us to expand our multinational Phase 3 PARADIGM program evaluating CYB003 for the potential adjunctive treatment of major depressive disorder. PARADIGM is a significantly larger program than the completed Phase 2 study, with anticipated combined enrollment of approximately 550 participants. Our Phase 3 studies will evaluate the potential clinical benefits of CYB003 in patients living with moderate to severe MDD, and whose symptoms are uncontrolled with existing antidepressant treatment. Our Phase 2 study evaluating CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month.' 'Cybin is in a strong position to advance our programs and continue our work to deliver innovative therapies to address some of the most challenging mental health disorders we face today and is helping to build momentum across the sector - both from a clinical and regulatory perspective,' concluded Drysdale. Recent Business and Pipeline Highlights: Received European approval and MHRA approval for EMBRACE, the second Phase 3 study within the PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD, on schedule. The Company has received CTA approval from the Irish Medicines Board for the EMBRACE study in Ireland, Poland, and Greece, as well as approval from the MHRA. EMBRACE is a 12-week, randomized, double-blind, placebo-controlled study in 330 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but with inadequate response. EMBRACE will evaluate two doses of CYB003 (8 mg, 16 mg) three weeks apart, compared to an inactive placebo. The primary endpoint is change in depressive symptoms as measured by the change in MADRS from baseline six weeks after the first dose. Making strong progress on CYB003 development through the APPROACH and EXTEND studies. Dosing is currently ongoing in the first pivotal study, APPROACH, which is expected to enroll 220 patients across 45 U.S. clinical sites. We are pleased to report that patient rollovers continue into EXTEND, the long-term extension study. Clinical Program Summary CYB003: Deuterated psilocin program Phase 3 PARADIGM program is underway, with topline data from first pivotal study, APPROACH, expected in 2026 1. CYB003 program accomplishments: Received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD. A completed Phase 2 study of CYB003 in MDD demonstrated durability of effect at 12 months: 100% of participants receiving two doses of 16 mg were responders. 71% of participants receiving two doses of 16 mg were in remission. Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses. CYB004: Deuterated dimethyltryptamine program The Phase 2 CYB004 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with generalized anxiety disorder, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. Patient enrollment is expected to be completed this month 1. Change in Presentation Currency Effective April 1, 2025, the Company changed its presentation currency from the Canadian dollar to the United States dollar (' USD '). The change in presentation currency was made to better reflect the Company's operations, align with the currency in which the majority of cash-based expenses are denominated, and improve comparability of its financial results with other publicly traded businesses in the industry. As a result, all amounts presented in this press release are in USD unless otherwise stated. First-Quarter Financial Highlights Cash totaled $118.7 million as of June 30, 2025. Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled $23.9 million for the quarter ended June 30, 2025, compared to $11.9 million, in the same period last year. Cash flows used in operating activities were $29.5 million for the quarter ended June 30, 2025, compared to $19.9 million in the same period last year. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Note: There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; the Company's expectation to complete enrollment in CYB004 Phase 2 study in August 2025; the Company's expectation to receive topline data from APPROACH in 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Time Business News
2 hours ago
- Time Business News
Trending News, Meta Gadget News, and the Best Smart Home Devices in 2025
Technology is evolving faster than ever, with innovations transforming how we live, work, and interact. Every day, trending news headlines showcase breakthroughs in artificial intelligence, augmented reality, and connected devices. Among the most closely watched developments are Meta gadget news, revealing how the social media giant continues to push boundaries in virtual experiences and smart technology. At the same time, the best smart home devices in 2025 are bringing futuristic living into reality, offering convenience, security, and energy efficiency that would have seemed impossible a decade ago. In the fast-paced tech world, trending news changes daily, reflecting major product launches, mergers, security updates, and AI advancements. Recently, several themes have dominated technology headlines: AI-Powered Everything – From chatbots to creative design tools, AI is now embedded in apps, wearables, and home automation systems. Eco-Friendly Tech – Companies are adopting sustainable manufacturing and low-energy products to appeal to environmentally conscious consumers. AR and VR Integration – Virtual reality headsets and augmented reality glasses are becoming mainstream, influencing gaming, training, and communication. Cybersecurity Priorities – Data protection and encrypted communications are taking center stage as privacy concerns rise. 5G and 6G Rollouts – Ultra-fast connectivity is enabling real-time gaming, instant cloud processing, and seamless streaming. For consumers and businesses alike, keeping up with trending news is the key to making informed tech decisions. Meta, the parent company of Facebook, Instagram, and WhatsApp, has gone beyond software to become a major player in hardware innovation. The Meta gadget news over the past year has been packed with exciting developments in AR, VR, and smart devices. Some of the most notable updates include: Meta Quest 4 VR Headset – Featuring lighter design, sharper visuals, and improved motion tracking, it's aimed at both gamers and professionals. – Featuring lighter design, sharper visuals, and improved motion tracking, it's aimed at both gamers and professionals. AR Glasses for Everyday Use – Sleek, stylish eyewear integrating messaging, navigation, and voice commands directly into your vision. – Sleek, stylish eyewear integrating messaging, navigation, and voice commands directly into your vision. AI-Powered Content Creation Tools – New Meta devices are making it easier for creators to produce short-form videos, livestreams, and interactive content. – New Meta devices are making it easier for creators to produce short-form videos, livestreams, and interactive content. Smart Communication Displays – Upgraded versions of Meta Portal devices now offer holographic calling, making virtual meetings feel more natural. – Upgraded versions of Meta Portal devices now offer holographic calling, making virtual meetings feel more natural. Meta Home AI Integration – Meta is stepping into the smart home ecosystem by making its devices compatible with popular automation platforms. These Meta gadget news updates show the company's dedication to connecting people in more immersive and intelligent ways. The best smart home devices in 2025 are not just about convenience—they are about creating a safer, more efficient, and more personalized living environment. Here's a roundup of the top devices making headlines this year. Advanced assistants like Amazon Alexa 5.0 and Google Nest AI can predict user needs, automate daily routines, and control all connected devices seamlessly. Smart thermostats now use AI to adapt to your schedule and even monitor weather forecasts to adjust heating and cooling for maximum efficiency. Cameras, locks, and alarm systems now integrate facial recognition, biometric verification, and AI threat detection for enhanced protection. From refrigerators that suggest recipes based on contents to ovens that can cook meals automatically, kitchen tech is redefining convenience. AI-powered energy meters and solar storage systems help households reduce electricity bills and carbon footprints. Smart TVs with holographic displays and voice gesture controls make movie nights feel like stepping into another world. From air purifiers that track allergens to smart beds that adjust firmness for better sleep, wellness tech is becoming a core part of the smart home. One of the most exciting aspects of Meta gadget news is how seamlessly these devices are starting to integrate with the best smart home devices in 2025. Imagine taking a holographic call on your Meta AR glasses while adjusting your thermostat with a voice command—or having your Meta AI assistant coordinate with your home's energy system to reduce costs during peak hours. Meta's move toward smart home compatibility could reshape the market, giving users a unified system for communication, entertainment, and automation. The tech world moves quickly, and yesterday's innovations can become outdated within months. By staying updated on trending news, you can: Make smarter purchasing decisions for gadgets and appliances. Take advantage of early adoption benefits before products become mainstream. Understand how evolving trends might impact your work, security, and lifestyle. If you're ready to upgrade your living space, consider these tips: Check Compatibility – Ensure your devices can connect with your preferred smart assistant or platform. Prioritize Security – Look for products with strong encryption and privacy controls. Think Long-Term – Choose devices that can receive software updates to stay relevant. Balance Cost and Features – High-end gadgets are tempting, but mid-range products often provide excellent value. Go Green – Opt for energy-efficient models to save money and reduce environmental impact. As trending news continues to highlight AI, AR, and IoT advancements, the integration between social platforms and smart home ecosystems will deepen. Meta's hardware efforts could make it a central player in future households, combining communication, entertainment, and automation in one ecosystem. By blending Meta gadget news with insights into the best smart home devices in 2025, we can see a clear direction: a future where technology not only connects people but also adapts to their lifestyles in ways that feel intuitive, secure, and personalized. From the latest trending news to groundbreaking Meta gadget news and the best smart home devices in 2025, the technology landscape is rich with opportunities for innovation and transformation. Meta's move into AR, VR, and smart home integration signals a new chapter in connected living, while the rise of AI-powered home devices promises unprecedented convenience and efficiency. By staying informed and choosing the right tools, we can all take part in shaping a smarter, more connected future. TIME BUSINESS NEWS
Business Wire
2 hours ago
- Business Wire
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to Arrowhead. This agreement pertains only to the $100 million milestone, which was announced on July 28, 2025, and earned after Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1). Any subsequent milestones earned will continue to be payable in cash. Sarepta previously owned 11,926,301 shares of Arrowhead stock. Today after market close, Sarepta sold the balance of its remaining holdings of Arrowhead common stock in a separate negotiated block trade. With a strong balance sheet anticipated to fund our company into fiscal 2028, we believe this direct stock buyback of Arrowhead shares from Sarepta is an attractive option, given Arrowhead's current stock price and the significant growth potential Share 'We are committed to supporting our broad and long-term collaboration and we are thrilled with the great progress we've made on multiple important clinical, preclinical, and discovery stage siRNA programs. While we remain confident that Sarepta will meet its financial obligations to Arrowhead, we believe reducing our outstanding shares by receiving approximately half of the $100 million due from Sarepta in cash and half in Arrowhead stock to be returned to treasury is a compelling opportunity,' said Christopher Anzalone, Ph.D., Arrowhead's President and CEO. 'With a strong balance sheet anticipated to fund our company into fiscal 2028, we believe this direct stock buyback of Arrowhead shares from Sarepta is an attractive option, given Arrowhead's current stock price and the significant growth potential, both near- and longer-term, as we pursue multiple commercial launches of wholly-owned and partnered candidates in the coming quarters and years.' About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Arrowhead Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as 'may,' 'will,' 'expect,' 'believe,' 'anticipate,' 'hope,' 'intend,' 'plan,' 'project,' 'could,' 'estimate,' 'continue,' 'target,' 'forecast' or 'continue' or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, including the timing of achievement of future milestones, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements, including our ability to achieve such milestones on projected timelines (if at all) and receive timely payment if milestones are achieved; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties; and our estimates for our projected cash runway. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We disclaim any intention to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.
